Dyax sales and marketing update

Dyax launched Kalbitor ecallantide to treat acute attacks of hereditary angioedema (HAE) in the U.S. Kalbitor is a subcutaneously delivered yeast-derived recombinant plasma kallikrein inhibitor. ...